Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00143884 · ClinicalTrials.gov registry record · Phase 2

Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood

A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.

Terminated
Registry status
Phase 2
Development phase
30
Enrollment target

NCT00143884 is a Phase 2 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00143884, a Phase 2 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.

TERMINATED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

This research project will focus on whether it is safe and effective to rely on donor cells to prevent relapse of leukemia, lymphoma, or other blood cancer after bone marrow stem cell transplant.

Interventions

  • PROCEDURE Reduced intensity conditioning
  • PROCEDURE Prophylactic donor leukocyte infusions

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2000-03
Phase Phase 2

What the Registry Record Tells You About NCT00143884

The ClinicalTrials.gov registry entry for NCT00143884 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Reduced intensity conditioning is the first listed.

NCT00143884 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00143884 about?

NCT00143884 is a clinical study titled "Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood". This research project will focus on whether it is safe and effective to rely on donor cells to prevent relapse of leukemia, lymphoma, or other blood cancer after bone marrow stem cell transplant.

What is the current status of trial NCT00143884?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2000-03.

What interventions are being tested in trial NCT00143884?

The interventions under investigation include: Reduced intensity conditioning (PROCEDURE), Prophylactic donor leukocyte infusions (PROCEDURE).

Who is sponsoring clinical trial NCT00143884?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.